Showing results (811-820 of 1,010) with videos related to

Sort By:
Pageof 101
Journal of Personalized Medicine|April 23, 2022
Predicting the Need for Therapeutic Intervention and Mortality in Acute Pancreatitis: A Two-Center International Study Using Machine LearningNa Shi, Lan Lan, Jiawei Luo, et al.
Kidney International. Supplement|February 11, 1975
Neurotoxicity in uremiaH E Ginn, P E Teschan, P J Walker, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|November 1, 1995
How important is race/ethnicity as an indicator of risk for specific AIDS-defining conditions?D J Hu, P L Fleming, K G Castro, et al.
The Journal of Burn Care & Rehabilitation|July 1, 1987
Prevalence of postburn depression following burn injuryH W Ward, R L Moss, D F Darko, et al.
Science Translational Medicine|May 13, 2011
Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopeniaTyesha N Burks, Eva Andres-Mateos, Ruth Marx, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 21, 2022
Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in JapanMd Razeen Ashraf Hussain, Lindsey Hiebert, Aya Sugiyama, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 1999
The inhibition of human cytomegalovirus (hCMV) protease by hydroxylamine derivativesD G Smith, A D Gribble, D Haigh, et al.
The Journal of Infectious Diseases|May 1, 1991
Comparison of spinal fluid beta 2-microglobulin levels with CD4+ T cell count, in vitro T helper cell function, and spinal fluid IgG parameters in 163 neurologically normal adults infected with the human immunodeficiency virus type 1D R Lucey, S A McGuire, M Clerici, et al.
Reviews of Infectious Diseases|November 1, 1986
A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infectionsJ F Reinhardt, L Johnston, P Ruane, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
6-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)Jason Witherington, Vincent Bordas, Alessandra Gaiba, et al.
Pageof 101